|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ENTPD7 |
Gene summary for ENTPD7 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ENTPD7 | Gene ID | 57089 |
| Gene name | ectonucleoside triphosphate diphosphohydrolase 7 | |
| Gene Alias | LALP1 | |
| Cytomap | 10q24.2 | |
| Gene Type | protein-coding | GO ID | GO:0001775 | UniProtAcc | Q9NQZ7 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 57089 | ENTPD7 | LZE4T | Human | Esophagus | ESCC | 5.60e-09 | 3.49e-01 | 0.0811 |
| 57089 | ENTPD7 | P2T-E | Human | Esophagus | ESCC | 5.58e-04 | 1.41e-01 | 0.1177 |
| 57089 | ENTPD7 | P5T-E | Human | Esophagus | ESCC | 1.62e-02 | 5.18e-02 | 0.1327 |
| 57089 | ENTPD7 | P9T-E | Human | Esophagus | ESCC | 3.16e-08 | 1.04e-01 | 0.1131 |
| 57089 | ENTPD7 | P11T-E | Human | Esophagus | ESCC | 9.05e-10 | 3.83e-01 | 0.1426 |
| 57089 | ENTPD7 | P16T-E | Human | Esophagus | ESCC | 5.48e-10 | 6.09e-02 | 0.1153 |
| 57089 | ENTPD7 | P20T-E | Human | Esophagus | ESCC | 3.79e-05 | 9.57e-02 | 0.1124 |
| 57089 | ENTPD7 | P21T-E | Human | Esophagus | ESCC | 5.61e-03 | 1.27e-01 | 0.1617 |
| 57089 | ENTPD7 | P22T-E | Human | Esophagus | ESCC | 2.93e-06 | 5.34e-02 | 0.1236 |
| 57089 | ENTPD7 | P23T-E | Human | Esophagus | ESCC | 3.30e-14 | 2.31e-01 | 0.108 |
| 57089 | ENTPD7 | P24T-E | Human | Esophagus | ESCC | 5.53e-04 | 5.37e-02 | 0.1287 |
| 57089 | ENTPD7 | P27T-E | Human | Esophagus | ESCC | 5.06e-03 | 7.45e-02 | 0.1055 |
| 57089 | ENTPD7 | P30T-E | Human | Esophagus | ESCC | 2.00e-08 | 3.24e-01 | 0.137 |
| 57089 | ENTPD7 | P32T-E | Human | Esophagus | ESCC | 4.36e-05 | 8.75e-02 | 0.1666 |
| 57089 | ENTPD7 | P36T-E | Human | Esophagus | ESCC | 6.41e-03 | 1.47e-01 | 0.1187 |
| 57089 | ENTPD7 | P37T-E | Human | Esophagus | ESCC | 3.82e-09 | 1.53e-01 | 0.1371 |
| 57089 | ENTPD7 | P39T-E | Human | Esophagus | ESCC | 4.60e-04 | 7.98e-02 | 0.0894 |
| 57089 | ENTPD7 | P42T-E | Human | Esophagus | ESCC | 1.92e-06 | 1.79e-01 | 0.1175 |
| 57089 | ENTPD7 | P44T-E | Human | Esophagus | ESCC | 6.75e-06 | 1.59e-01 | 0.1096 |
| 57089 | ENTPD7 | P47T-E | Human | Esophagus | ESCC | 6.75e-08 | 1.89e-01 | 0.1067 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0034655110 | Esophagus | ESCC | nucleobase-containing compound catabolic process | 272/8552 | 407/18723 | 2.92e-18 | 2.90e-16 | 272 |
| GO:004670018 | Esophagus | ESCC | heterocycle catabolic process | 286/8552 | 445/18723 | 1.12e-15 | 7.47e-14 | 286 |
| GO:004427019 | Esophagus | ESCC | cellular nitrogen compound catabolic process | 288/8552 | 451/18723 | 3.03e-15 | 1.79e-13 | 288 |
| GO:001943918 | Esophagus | ESCC | aromatic compound catabolic process | 295/8552 | 467/18723 | 1.09e-14 | 5.98e-13 | 295 |
| GO:190136118 | Esophagus | ESCC | organic cyclic compound catabolic process | 307/8552 | 495/18723 | 9.99e-14 | 4.80e-12 | 307 |
| GO:0006753110 | Esophagus | ESCC | nucleoside phosphate metabolic process | 288/8552 | 497/18723 | 1.80e-08 | 3.50e-07 | 288 |
| GO:0019693111 | Esophagus | ESCC | ribose phosphate metabolic process | 234/8552 | 396/18723 | 4.24e-08 | 7.76e-07 | 234 |
| GO:0009117111 | Esophagus | ESCC | nucleotide metabolic process | 282/8552 | 489/18723 | 4.70e-08 | 8.50e-07 | 282 |
| GO:0009141111 | Esophagus | ESCC | nucleoside triphosphate metabolic process | 78/8552 | 112/18723 | 2.36e-07 | 3.59e-06 | 78 |
| GO:0009259111 | Esophagus | ESCC | ribonucleotide metabolic process | 224/8552 | 385/18723 | 4.41e-07 | 6.00e-06 | 224 |
| GO:0072521111 | Esophagus | ESCC | purine-containing compound metabolic process | 238/8552 | 416/18723 | 1.20e-06 | 1.49e-05 | 238 |
| GO:0009150111 | Esophagus | ESCC | purine ribonucleotide metabolic process | 213/8552 | 368/18723 | 1.40e-06 | 1.69e-05 | 213 |
| GO:0006163111 | Esophagus | ESCC | purine nucleotide metabolic process | 226/8552 | 396/18723 | 2.81e-06 | 3.21e-05 | 226 |
| GO:0009144110 | Esophagus | ESCC | purine nucleoside triphosphate metabolic process | 61/8552 | 88/18723 | 6.06e-06 | 6.23e-05 | 61 |
| GO:000919918 | Esophagus | ESCC | ribonucleoside triphosphate metabolic process | 61/8552 | 89/18723 | 1.07e-05 | 1.01e-04 | 61 |
| GO:000920519 | Esophagus | ESCC | purine ribonucleoside triphosphate metabolic process | 55/8552 | 82/18723 | 7.34e-05 | 5.51e-04 | 55 |
| GO:000913219 | Esophagus | ESCC | nucleoside diphosphate metabolic process | 77/8552 | 124/18723 | 1.65e-04 | 1.09e-03 | 77 |
| GO:000918520 | Esophagus | ESCC | ribonucleoside diphosphate metabolic process | 66/8552 | 106/18723 | 4.21e-04 | 2.39e-03 | 66 |
| GO:00062203 | Esophagus | ESCC | pyrimidine nucleotide metabolic process | 35/8552 | 50/18723 | 4.33e-04 | 2.44e-03 | 35 |
| GO:00091473 | Esophagus | ESCC | pyrimidine nucleoside triphosphate metabolic process | 20/8552 | 25/18723 | 4.81e-04 | 2.69e-03 | 20 |
| Page: 1 2 3 4 5 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ENTPD7 | SNV | Missense_Mutation | c.696N>A | p.Phe232Leu | p.F232L | Q9NQZ7 | protein_coding | tolerated(0.06) | possibly_damaging(0.685) | TCGA-A2-A0EQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
| ENTPD7 | SNV | Missense_Mutation | c.1069N>T | p.Pro357Ser | p.P357S | Q9NQZ7 | protein_coding | deleterious(0.03) | probably_damaging(0.998) | TCGA-A2-A25E-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | PD | |
| ENTPD7 | SNV | Missense_Mutation | c.883G>C | p.Gly295Arg | p.G295R | Q9NQZ7 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A8-A07R-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Ancillary | zoledronic | SD | |
| ENTPD7 | SNV | Missense_Mutation | c.1054C>G | p.Leu352Val | p.L352V | Q9NQZ7 | protein_coding | tolerated(0.1) | benign(0.292) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| ENTPD7 | SNV | Missense_Mutation | novel | c.772N>T | p.Asp258Tyr | p.D258Y | Q9NQZ7 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-AN-A0AR-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| ENTPD7 | SNV | Missense_Mutation | c.1622N>A | p.Ser541Asn | p.S541N | Q9NQZ7 | protein_coding | tolerated(0.33) | benign(0.003) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
| ENTPD7 | SNV | Missense_Mutation | c.1377N>G | p.Phe459Leu | p.F459L | Q9NQZ7 | protein_coding | tolerated(0.1) | benign(0.05) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD | |
| ENTPD7 | SNV | Missense_Mutation | rs753602972 | c.76C>T | p.Arg26Cys | p.R26C | Q9NQZ7 | protein_coding | tolerated(0.11) | possibly_damaging(0.871) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| ENTPD7 | SNV | Missense_Mutation | c.1662C>G | p.Phe554Leu | p.F554L | Q9NQZ7 | protein_coding | tolerated(0.15) | benign(0.028) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD | |
| ENTPD7 | SNV | Missense_Mutation | novel | c.739N>A | p.Ala247Thr | p.A247T | Q9NQZ7 | protein_coding | tolerated(0.54) | benign(0.014) | TCGA-VS-A958-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |